Alterity Therapeutics Limited

ATHE

$4.52

+0.00%

N/A+$0.00

Healthcare

Biotechnology

NASDAQ

Active Trading

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such ...

Fundamental Analysis of ATHE

Key Strengths

Lead candidate ATH434 is supported by Phase 2 randomized placebo-controlled efficacy signals in MSA (modified UMSARS Part I) plus supportive secondary measures

Biomarker and imaging strategy (e.g., brain iron/quantitative MRI and related markers) provides target-engagement plausibility rather than relying solely on clinical scales

Risk Factors

Clinical-stage binary risk: Phase 3 success is not guaranteed despite Phase 2 signals; endpoints, effect size, and heterogeneity of MSA can affect outcomes

Financing and dilution risk: negative operating cash flow/FCF and lack of revenue mean future capital raises may dilute shareholders

Profitability

Net Margin0.00%

Operating Margin0.00%

Valuation

P/E Ratio-4.53x

Current Ratio14.52

Efficiency

ROE-48.25%

ROA-50.85%

Fundamental Analysis of ATHE

Alterity Therapeutics (ATHE) is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, with its primary focus on Multiple System Atrophy (MSA). The company’s lead program, ATH434, is an oral agent positioned to inhibit pathological protein aggregation and address disrupted brain iron homeostasis. Fundamentally, ATHE’s investment thesis is centered on whether ATH434 can translate promising Phase 2 efficacy and biomarker/target-engagement signals into a successful, registrational Phase 3 program in MSA. From a competitive-position standpoint, the company has multiple supportive non-financial indicators: (1) reported positive Phase 2 outcomes in a randomized, double-blind, placebo-controlled study (ATH434-201) using modified UMSARS Part I functional endpoints; (2) additional supportive findings from an open-label Phase 2 biomarker study (ATH434-202), including trends consistent with reduced brain iron accumulation and stabilized neurodegenerative markers; and (3) regulatory engagement—Fast Track designation and Orphan Drug designation—plus FDA feedback indicating a clear registrational pathway. Importantly, the market catalyst calendar indicates Phase 3 initiation in late 2026, which can materially re-rate expectations if enrollment and execution are strong. Financially, ATHE remains pre-commercial and therefore does not have meaningful revenue or operating profitability. The available TTM indicators show negative profitability metrics (net margin and operating/EBIT margins are negative), negative free cash flow, and weak cash-flow coverage ratios typical of R&D-driven biotechs. Balance-sheet liquidity appears strong via a very high current ratio/quick ratio, but this should be interpreted in the context of a development-stage company that relies on financing and clinical milestones rather than internally generated operating cash. Valuation ratios tied to earnings are not meaningful (negative P/E). Given micro-cap scale and high sensitivity to capital markets, dilution risk is a persistent fundamental concern. Overall, ATHE is best evaluated as an event-driven clinical probability product with a credible, regulator-aligned Phase 3 plan and meaningful scientific rationale, balanced against execution risk, trial outcome uncertainty, and ongoing financing needs.

Key Strengths of ATHE

Lead candidate ATH434 is supported by Phase 2 randomized placebo-controlled efficacy signals in MSA (modified UMSARS Part I) plus supportive secondary measures
Biomarker and imaging strategy (e.g., brain iron/quantitative MRI and related markers) provides target-engagement plausibility rather than relying solely on clinical scales
Regulatory momentum: FDA Fast Track designation and Orphan Drug designation, with documented alignment on the intended registrational pathway
Intellectual property momentum: company reports new U.S. composition of matter patent approvals supporting the program’s defensibility
Well-defined near-term catalyst runway with planned Phase 3 initiation in late 2026, including an agreed FDA design and active preparatory work
Strong liquidity signals in current/quick ratios relative to typical biotech peers, supporting runway into clinical milestones (though still financing-sensitive)

Risk Factors of ATHE

Clinical-stage binary risk: Phase 3 success is not guaranteed despite Phase 2 signals; endpoints, effect size, and heterogeneity of MSA can affect outcomes
Financing and dilution risk: negative operating cash flow/FCF and lack of revenue mean future capital raises may dilute shareholders
Manufacturing/CMC and regulatory execution risk: even with FDA alignment, Phase 3 requires robust CMC, trial operations, site activation, and enrollment execution
Small-company volatility and liquidity: micro-cap dynamics can amplify price swings unrelated to fundamental changes
Endpoint sensitivity in MSA: the disease is rare and rapidly progressive, and clinical rating scales/biomarker variability may impact statistical robustness
Competitive and standards-of-care evolution risk: other therapeutic approaches or shifting treatment paradigms could reduce ATH434’s relative value if Phase 3 is delayed

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$76.57M

-4.5x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin0.00%

Net Profit Margin0.00%

Debt/Equity Ratio0.00

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of ATHE

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of ATHE

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	0.00%	—	—	Flat
Operating Margin	—	0.00%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of ATHE

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	14.520	—	—	Flat
Quick Ratio	—	14.520	—	—	Flat
Debt / Equity	—	0.005	—	—	Flat

Valuation of ATHE

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-2.49x	—	—	Flat
P/B	—	3.29x	—	—	Flat

Supply Chain of ATHE

RELATIONS

Upstream

Contract Development and Manufacturing Organization (CDMO) – ATH434 Drug Substance ManufacturerClinical Research Organization (CRO) – Clinical Trial ManagementVanderbilt University Medical CenterMichael J. Fox Foundation for Parkinson's ResearchPricewaterhouseCoopers (PwC) AustraliaNYSE:PWCSpecialty raw chemical / reagent suppliers (via CDMO)Clinical trial site institutions (hospitals & clinics – US, UK, Australia)

Downstream

Professor Colin Masters (Licensee – AH Patent Assets)Potential Strategic Pharmaceutical Collaborators (Undisclosed)

Proxies

Biohaven Pharmaceutical Holding Company Ltd.NYSE:BHVN Prothena Corporation plcNASDAQ:PRTA Acorda Therapeutics (historical)NASDAQ:ACOR Cognition Therapeutics Inc.NASDAQ:CGTX

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer